Victory Square Technologies: Trading at a Deep Discount to Its Tangibly Growing Net Asset Value, Poised for Rerating Amid Structural and Strategic Advances
Victory Square Technologies Inc. (VST) operates as a publicly-traded "venture builder," a unique model that provides retail and institutional investors with liquid, audited, and transparent access to a diversified portfolio of early-stage technology companies. This structure aims to democratize venture capital-style investing, an asset class typically restricted to accredited investors through illiquid, multi-year commitment funds. The company's investment portfolio, comprising over 25 private and public entities, is strategically focused on high-growth, disruptive sectors. The primary concentration is in Digital Health, which serves as the company's core operational and value driver. Other key verticals include Artificial Intelligence (AI), Gaming and Immersive Technologies, and Climate Tech.
The central investment thesis for Victory Square Technologies is the profound and quantifiable discount at which its shares trade relative to the underlying Net Asset Value (NAV) of its holdings. The company's public market capitalization is currently less than the mark-to-market value of its majority ownership stake in just one of its portfolio companies, the publicly-listed Hydreight Technologies Inc. (TSXV: NURS). This valuation anomaly implies that the market is ascribing a negative value to the remainder of VST's diversified portfolio, its cash reserves, and its experienced management team. A series of recent positive developments, including a newly initiated share buyback program, the elimination of all corporate debt, and the continued operational success of its core assets, present clear catalysts that could compel a re-rating and close this significant valuation gap over time.
Victory Square's revenue and value creation are driven by a dual-engine model: the operational performance of its consolidated subsidiaries and the strategic monetization of its venture portfolio.
A substantial portion of VST's reported GAAP revenue is derived from the consolidation of its majority-owned subsidiary, Hydreight Technologies. For the fiscal year 2024, Hydreight's $16.0 million in GAAP revenue accounted for the vast majority of VST's total reported revenue of $16.7 million. This highlights Hydreight's critical role not just as a key asset, but as the primary operational engine reflected in VST's current financial statements. The consistent, recurring revenue from Hydreight's platform provides a stable base for the consolidated entity.
The second crucial driver of value is the strategic and opportunistic monetization of other portfolio assets. This process involves selling stakes in mature or non-core companies to generate capital for reinvestment and shareholder returns. Notable recent examples include the sale of BlockX to Edge Total Intelligence for $1.7 million in listed shares in 2024 and the disposition of certain AI fintech solutions to Yocale.ai for approximately $880,000 in equity in the first quarter of 2025. These monetization events, while generating non-recurring gains, are fundamental to the venture builder model. They validate the incubation process, provide non-dilutive funding for new ventures, and demonstrate the ability to crystallize value from the portfolio.
VST's forward-looking growth is anchored by its key portfolio assets, each at a different stage of its lifecycle.
Hydreight Technologies (TSXV: NURS): As VST's crown jewel and primary growth engine, Hydreight (approximately 58% ownership) is a digital health company that has achieved significant scale and profitability. Its core offering, the VSDHOne platform, provides a turnkey telehealth and e-pharmacy infrastructure that enables the rapid launch of compliant direct-to-consumer healthcare brands across all 50 U.S. states. The platform's success is evidenced by its rapid revenue growth (39% year-over-year in 2024) and its achievement of profitability, marked by three consecutive profitable quarters as of Q2 2025. This asset provides VST with exposure to the resilient and expanding telehealth market.
Insu Therapeutics: Representing a high-risk, high-reward venture, VST's 22.8% stake in Insu Therapeutics offers significant, albeit speculative, upside potential. Insu is developing a patent-pending oral insulin tablet designed as an alternative to daily injections for individuals with diabetes. A breakthrough in this area would be transformative, targeting a global diabetes therapeutics market projected to reach $118 billion by 2032. The most critical near-term milestone for Insu is the targeted commencement of first-in-human trials in 2026, which will be a major validation point for the technology.
Pawsible Ventures & New Incubations: VST continues to execute its venture builder mandate by incubating new companies in large, underserved markets. Pawsible Ventures, in which VST holds a 49% stake, aims to apply the successful telehealth and wellness platform model to the burgeoning pet care industry, a market expected to reach $368 billion by 2030. This initiative, along with a new $10 million Health Accelerator, demonstrates the company's strategy of leveraging its expertise and existing infrastructure (like the VSDHOne platform) to build new, scalable businesses.
VST's business model is fortified by several distinct competitive advantages. The company's publicly-traded venture builder structure is a key differentiator, offering investors liquidity and transparency that are absent in traditional, closed-end venture capital funds. This unique positioning democratizes access to early-stage tech investing.
The company also cites unparalleled access to deal flow through its internal incubators and a vast global network of over 80 accelerator partners, ensuring a steady stream of investment opportunities. Unlike passive investors, VST's management team and advisors are actively involved in their portfolio companies, providing hands-on financial, operational, and strategic support from incubation through to monetization.
Crucially, management's interests are strongly aligned with those of shareholders. Insiders own approximately 15% of the company, demonstrating significant "skin in the game". This alignment is further reinforced by recent strategic decisions, most notably the initiation of a Normal Course Issuer Bid (NCIB) to buy back up to 5% of its outstanding shares. This action serves as a clear signal from management that it believes the stock is fundamentally undervalued and represents a prudent use of capital to enhance shareholder value.
The combination of these factors suggests a significant evolution in the business model. Historically, as a venture incubator, VST was reliant on external capital markets to fund its operations and portfolio, a reality reflected in the auditor's "going concern" note in past financial statements. However, the public listing and subsequent success of Hydreight have created a massive, liquid asset on VST's balance sheet. This, coupled with the active monetization of non-core assets like BlockX, has transformed VST into a self-sustaining entity. It can now fund new ventures, support its existing portfolio, and return capital to shareholders using its own resources, thereby reducing its dependence on potentially dilutive equity financing and creating a virtuous cycle of value creation.
Victory Square's recent financial results illustrate a significant operational turnaround and a clear trajectory toward sustainable profitability. For the full fiscal year ended December 31, 2024, the company reported GAAP revenue of $16.7 million, a robust 39% increase from the $12.1 million reported in 2023. Gross margin also expanded to $6.4 million for the year.
This positive momentum accelerated into 2025. For the six months ended June 30, 2025, VST reported adjusted revenue of $13.9 million, a 33% increase year-over-year. More importantly, the company reached a critical inflection point, reporting positive Adjusted EBITDA of $463,000 for the first half of the year. This marks a dramatic improvement from the Adjusted EBITDA loss of $1.59 million recorded in the same period of 2024 and signals growing operational leverage and efficiency. The company's balance sheet was also materially strengthened in September 2025 when it cleared all outstanding corporate debt by executing a pre-negotiated conversion into Hydreight shares, leaving VST with a clean financial slate and a substantial holding in its primary public asset.
The table below summarizes key historical financial metrics, highlighting the company's growth and recent turn to profitability.
Data sourced from company press releases.
The most appropriate method for valuing a holding company like VST is a Sum-of-the-Parts (SOTP) analysis, which assesses the value of each of its assets individually. This approach reveals a stark disconnect between the company's intrinsic value and its current public market valuation.
The cornerstone of this valuation is VST's stake in Hydreight. As of a September 22, 2025 update, VST held 25,326,124 shares of NURS.V. By valuing this position at its daily market price, we can establish a liquid, mark-to-market value for VST's largest asset. The valuation of private assets like Insu Therapeutics is more subjective. A conservative approach is applied, using estimates based on comparable pre-clinical biotech assets and recent financing rounds rather than speculative future outcomes. The remaining portfolio of public and private companies is valued at market prices or conservative book values.
The following SOTP table, based on data available in late 2025, quantifies the significant discount to Net Asset Value at which VST shares are currently trading.
| Asset Component | Ownership % | Quantity / Basis of Value | Value (CAD) | Per VST Share (CAD) | Source |
| Public & Liquid Assets | |||||
| Hydreight (NURS.V) | ~58% | 25.3M shares @ C$4.83 | C$122.3M | C$1.21 | |
| Cash & Marketable Securities | N/A | As of Q1 2025 | C$9.7M | C$0.10 | |
| Other Public Holdings (TTGI, FANS, etc.) | Various | Market Price | C$2.0M (Est.) | C$0.02 | |
| Subtotal Liquid Assets | C$134.0M | C$1.33 | |||
| Private & Illiquid Assets | |||||
| Insu Therapeutics | 22.8% | Pre-clinical biotech | C$10.0M (Est.) | C$0.10 | |
| Pawsible Ventures | 49% | Seed-stage incubator | C$2.5M (Est.) | C$0.02 | |
| Remainder of Portfolio (20+ cos.) | Various | Book Value / Last Round | C$10.0M (Est.) | C$0.10 | |
| Gross Asset Value (GAV) | C$156.5M | C$1.55 | |||
| Liabilities & Adjustments | |||||
| Corporate Debt | N/A | Cleared in Sep 2025 | C$0.0M | C$0.00 | |
| Corporate G&A (Present Value) | N/A | 5-yr estimate | (C$5.0M) | (C$0.05) | Estimate |
| Net Asset Value (NAV) | C$151.5M | C$1.50 | |||
| Current Market Cap (@ C$0.78/share) | C$78.75M | C$0.78 | |||
| Discount to NAV | ~48% |
Based on 100.96M shares outstanding.
Despite the compelling valuation, an investment in Victory Square Technologies is subject to several material risks.
Concentration Risk: The company's valuation is overwhelmingly dependent on the market performance of its Hydreight stake. Any material adverse developments at Hydreight—such as slowing growth, increased competition, or regulatory hurdles—would severely and directly impact VST's NAV and share price.
Execution and Venture Risk: The success of early-stage ventures like Insu Therapeutics and Pawsible Ventures is inherently uncertain and highly speculative. The probability of failure for any single early-stage company is high, and investors should anticipate that some portfolio companies will result in a total loss of invested capital.
Holding Company Discount: Publicly-traded holding and investment companies often trade at a persistent discount to their NAV. This discount can be attributed to factors such as perceived corporate overhead, potential for capital misallocation, or tax inefficiencies upon asset sales. There is no guarantee that the current discount will narrow, even if the underlying assets perform well.
Valuation Subjectivity: While the Hydreight stake has a liquid market value, the valuation of the private portfolio is based on management estimates and can be highly subjective. This was noted by the company's auditors as a "Key Audit Matter" in the 2024 financial statements, requiring a high degree of judgment to assess fair value.
Legacy "Going Concern" Note: Although recent financial improvements may render it outdated, the auditor's warning in the FY2024 financials regarding a "material uncertainty related to going concern" remains a historical red flag. This note, based on past losses and working capital deficiencies, could continue to deter more risk-averse institutional investors until a consistent track record of profitability is established.
The nature of these risks has evolved significantly. The "Going Concern" risk noted by auditors was based on the financial state as of December 31, 2024. The subsequent elimination of all corporate debt and the crystallization of over C$120 million in a single, liquid public stock holding in September 2025 have fundamentally altered this picture. A company with this asset base is not at imminent risk of insolvency. Consequently, the primary forward-looking risk has shifted from one of survival to one of strategy. The critical question for investors is no longer if the company will survive, but rather how management will deploy the immense value generated by Hydreight. Prudent capital allocation through accretive buybacks and wise reinvestments could unlock substantial value, whereas missteps could squander this opportunity.
VST's performance is also subject to broader macroeconomic trends impacting the technology and venture capital sectors.
Venture Capital Market Health: The current global venture capital market is characterized by a "bifurcation." While funding for select, high-demand sectors like Artificial Intelligence remains robust, the overall climate for fundraising and exits has become more challenging. A prolonged downturn in the broader VC market could make it difficult for VST to monetize its non-Hydreight assets at attractive valuations, potentially delaying value realization.
Interest Rate Environment: Persistently high interest rates tend to compress valuation multiples for growth-oriented technology companies, as future cash flows are discounted at a higher rate. This could negatively impact the market values of VST's public holdings and the potential exit valuations for its private portfolio companies.
Technology Sector Trends: VST is strategically positioned to benefit from powerful secular growth trends in Digital Health and AI. However, the technology sector also faces significant scaling challenges related to the immense demand for computing power, data center infrastructure, and energy, alongside intense global competition for talent and market leadership.
This section presents a five-year scenario analysis to model potential total returns for VST.CN. The methodology is based on a dynamic Sum-of-the-Parts (SOTP) model, projecting the value of key assets forward under three distinct scenarios. The final 2030 share price is derived from the projected NAV, adjusted by a terminal holding company discount. All key inputs and assumptions are explicitly stated. The number of shares outstanding is assumed to decrease by 5% over the period due to the full execution of the announced NCIB.
This scenario assumes solid execution but faces moderate headwinds.
Key Fundamentals: Hydreight (NURS.V) continues its growth trajectory, with revenue compounding at a 20% CAGR over the next five years. As the company matures, its valuation multiple compresses to a reasonable 3.0x sales. Insu Therapeutics fails to meet its primary endpoints in early clinical trials, leading to a significant write-down, but it retains a residual value of C$5 million for its intellectual property. The rest of VST's venture portfolio achieves a modest 1.5x return on its current estimated value through a mix of small exits and write-offs. A persistent 20% holding company discount to NAV is applied to VST's final valuation.
Projected 2030 NAV/Share: C$2.80
Projected 2030 Share Price (with 20% discount): C$2.24
This scenario represents successful execution across multiple key assets.
Key Fundamentals: Hydreight's platform strategy gains significant market share, driving revenue growth at an accelerated 30% CAGR and justifying a premium 5.0x sales multiple. The most significant catalyst is realized as Insu Therapeutics reports positive data from its Phase 1/2 trials, causing its valuation to step up dramatically to C$150 million. VST's venture building expertise shines as it successfully exits several other portfolio companies, achieving a strong 4.0x return on the "rest of portfolio" segment. Strong operational performance and a clear capital return policy cause the NAV discount to narrow to just 10%.
Projected 2030 NAV/Share: C$6.50
Projected 2030 Share Price (with 10% discount): C$5.85
This conservative scenario models significant challenges and asset impairment.
Key Fundamentals: Hydreight faces intense competition and market saturation, causing its growth to slow to a 5% CAGR. Its valuation multiple erodes to 1.0x sales, in line with slower-growth healthcare service companies. Insu Therapeutics' oral insulin program is discontinued after failing to show efficacy, resulting in a complete C$0 write-off of the asset. A difficult venture capital exit market leads to a 50% write-down of the remaining portfolio. Investor confidence wanes due to poor execution, causing the holding company discount to widen to 40%.
Projected 2030 NAV/Share: C$0.85
Projected 2030 Share Price (with 40% discount): C$0.51
The table below illustrates the potential share price evolution under each scenario.
The probability-weighted price target is calculated by multiplying each scenario's outcome by its assigned probability and summing the results:
This probability-weighted 5-year price target of C0.78. The analysis indicates a highly favorable risk/reward profile, where the potential upside in the base and high cases significantly outweighs the potential downside in the low case.
ASYMMETRIC UPSIDE
This scorecard provides a structured assessment of qualitative factors critical to VST's long-term success, with each metric scored on a scale of 1 (poor) to 10 (excellent).
| Metric | Score (1-10) | Narrative Justification |
| Management Alignment | 8 | High insider ownership of approximately 15% and a long CEO tenure (since 2015) demonstrate commitment. The recently initiated NCIB is a strong, shareholder-friendly signal that management believes the stock is undervalued. |
| Revenue Quality | 5 | Revenue is growing rapidly but remains highly concentrated in a single subsidiary, Hydreight. Value creation from the rest of the portfolio relies on lumpy, non-recurring gains from asset sales, which are of lower quality than recurring operational revenue. |
| Market Position | 7 | The core asset, Hydreight, is a recognized high-growth leader in its niche, as evidenced by its inclusion in the Deloitte Technology Fast 50. VST itself is a small player in the broader venture capital and asset management industry. |
| Growth Outlook | 8 | The outlook is strong, underpinned by the proven, high-growth engine of Hydreight. This is complemented by the massive, albeit speculative, upside potential from ventures like Insu Therapeutics, which are targeting enormous addressable markets. |
| Financial Health | 6 | Financial health has improved dramatically. The balance sheet is now strong with significant liquid assets and zero corporate debt. The score is tempered by the historical "going concern" note from auditors and a track record of past losses. |
| Business Viability | 7 | The venture builder model has been validated by the success of Hydreight, which serves as a powerful proof of concept. The business has now transitioned to a self-funding model, enhancing its long-term viability. |
| Capital Allocation | 8 | Recent decisions have been astute. Management avoided dilutive financing in 2022 to fund Hydreight's growth and initiated a highly accretive share buyback in 2025. The future allocation of value from the Hydreight stake remains the key variable. |
| Analyst Sentiment | 4 | Analyst coverage is very limited, which is typical for a company of this size. The available consensus target price of C$0.35 is significantly below the current share price, suggesting either deep skepticism or, more likely, outdated research that does not reflect recent positive developments. |
| Profitability | 5 | The company has recently inflected to positive Adjusted EBITDA, a major milestone. However, consistent GAAP profitability is not yet established and often relies on one-time gains from asset revaluations or sales. |
| Track Record | 6 | The track record is mixed. Management has successfully incubated and taken public a major success story in Hydreight. However, the long-term stock chart shows extreme volatility and long periods of significant shareholder value destruction. |
| Blended Score | 6.4 / 10 |
IMPROVING FUNDAMENTALS
Victory Square Technologies presents a compelling and asymmetric special situation investment. The company's market value is demonstrably and significantly disconnected from the tangible, intrinsic value of its underlying assets. This gap is most pronounced when considering its large, liquid ownership stake in the rapidly growing and newly profitable Hydreight Technologies. The market is effectively offering investors the opportunity to acquire this core asset at a substantial discount, while ascribing little to no value to the rest of the venture portfolio, which includes a free "call option" on a potential breakthrough in diabetes treatment.
Key catalysts are in place that could force a re-evaluation of the company's worth. The execution of the NCIB at current prices should be highly accretive to NAV per share while providing a support level for the stock. Continued strong quarterly performance from Hydreight will organically grow the value of VST's largest asset. Any positive news flow from Insu Therapeutics regarding its pre-clinical or future clinical progress could serve as a powerful re-rating event. Finally, further strategic monetization of other portfolio assets, coupled with a clear strategy for returning capital to shareholders, could help to permanently narrow the holding company discount.
The investment is not without considerable risks. The heavy concentration in Hydreight makes VST highly sensitive to its performance. The venture and biotech portfolio is speculative by nature, and the deep valuation discount could persist if management fails to execute or allocate capital effectively. However, the investment thesis is built on the foundation that the current market price offers a highly favorable and asymmetric risk/reward profile. The recent fundamental improvements—a clean balance sheet, positive Adjusted EBITDA, and shareholder-friendly capital allocation—provide a solid foundation for future value realization.
DEEPLY UNDERVALUED
VST.CN has experienced a period of exceptionally strong price performance, with share price gains exceeding 700% over the past year. The stock is currently trading approximately 122% above its 200-day moving average, a clear indicator of powerful long-term bullish momentum. Recent fundamental news, particularly the September 2025 announcements detailing the clearing of the balance sheet and the initiation of the share buyback, has acted as a potent catalyst, propelling the stock to new 52-week highs. The short-term outlook remains constructive, supported by this positive fundamental momentum and technical strength. The ongoing NCIB should provide a technical floor for the share price and help absorb potential profit-taking.
STRONG MOMENTUM
View Victory Square Technologies Inc. (VST.CN) stock page
Loading the interactive version of this report…